Intervention

Droxidopa

ClinicalTrials.gov intervention label

Clinical trials13

Recruiting1

Common conditions19

Lead sponsors shown8

Clinical trials

13 shown

Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic FailureNCT02897063 · 2016-09-01

Safety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismNCT03446807 · 2021-12-01

Brain Perfusion & Oxygenation in Parkinson's Disease With NOHNCT03229174 · 2018-08-23

Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)NCT03567447 · 2018-08-17

Norepinephrine-targeted Therapy for Action Control in Parkinson DiseaseNCT03115827 · 2017-04-18

Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's DiseaseNCT02066571 · 2015-03-01

A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa TherapyNCT01927055 · 2013-11-01

Droxidopa / Pyridostigmine in Orthostatic HypotensionNCT01370512 · 2011-11-01

ENROLLING_BY_INVITATION

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's DiseaseNCT01176240 · 2010-06-01

A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using DroxidopaNCT00782340 · 2008-09-01

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)NCT00633880 · 2008-01-01

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)NCT00738062 · 2008-01-01

Augmenting Effects of L-DOPS With Carbidopa and EntacaponeNCT00547911 · 2007-10-01

Common conditions

Parkinson Disease6 Dopamine Beta Hydroxylase Deficiency4 Multiple System Atrophy4 Orthostatic Hypotension3 Parkinson's Disease3 Neurogenic Orthostatic Hypotension2 Non-diabetic Neuropathy2 Primary Autonomic Failure2 Pure Autonomic Failure2 Symptomatic Neurogenic Orthostatic Hypotension (NOH)2 Autonomic Failure1 Autonomic Nervous System Diseases1 Cognitive Ability, General1 Falls Patient1 Freezing of Gait1 Multiple Systems Atrophy1 Non-Diabetic Autonomic Neuropathy1 Progressive Supranuclear Palsy1 Symptomatic Neurogenic Orthostatic Hypotension1

Leading sponsors

Chelsea Therapeutics5 Vanderbilt University Medical Center2 Henry Ford Health System1 Loma Linda University1 Mayo Clinic1 National Institute of Neurological Disorders and Stroke (NINDS)1 St. Joseph's Hospital and Medical Center, Phoenix1 William Ondo, MD1

Trial status mix

COMPLETED6

TERMINATED2

UNKNOWN2

ENROLLING_BY_INVITATION1

RECRUITING1

WITHDRAWN1

Phase mix

PHASE25

PHASE35

PHASE12

PHASE42

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.